Arvinas (ARVN), with its partner Pfizer (PFE), announced that the FDA has accepted the new drug application for vepdegestrant for the treatment of patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy. The FDA has assigned a Prescription Drug User Fee Act action date of June 5, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating
- Arvinas price target raised to $24 from $18 at H.C. Wainwright
- Arvinas price target lowered to $16 from $19 at Wells Fargo
- Arvinas Holding Company: Strong Cash Position and Promising Pipeline Justify Buy Rating
- Arvinas Reports Q2 2025 Financials and Drug Developments